Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi
Candida and Aspergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for...
Gespeichert in:
| Veröffentlicht in: | Journal of Clinical Microbiology 2006-12, Vol.44 (12), p.4342-4344 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4344 |
|---|---|
| container_issue | 12 |
| container_start_page | 4342 |
| container_title | Journal of Clinical Microbiology |
| container_volume | 44 |
| creator | Isham, N Ghannoum, M.A |
| description | Candida and Aspergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for the organisms. The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined. The MICs of AMN for 25 strains each of non-Candida albicans Candida spp. (including Candida parapsilosis, Candida krusei, Candida guilliermondii, and Candida tropicalis), Aspergillus fumigatus, Scedosporium spp., Fusarium spp., and zygomycetes (including Absidia, Mucor, and Rhizopus spp.) were determined by using the Clinical and Laboratory Standards Institute M27-A2 and M38-A methodologies for yeasts and filamentous molds, respectively. The MIC ranges of AMN for all yeasts were similar (0.03 to 4.0 μg/ml), while the MIC ranges of AMN for filamentous fungi were species specific. AMN demonstrated potent antifungal activity against A. fumigatus, limited activity against Scedosporium spp., and no activity against zygomycetes or Fusarium spp. Our data showed that AMN demonstrated potent antifungal activities against all of the yeasts and Aspergillus isolates tested, suggesting that AMN could be an important addition to our arsenal of antifungals for the treatment of invasive fungal disease. |
| doi_str_mv | 10.1128/JCM.01550-06 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_highw</sourceid><recordid>TN_cdi_highwire_asm_jcm_44_12_4342</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20206305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-d7755dd5279e506c09b692b2c81ce65650c9faf75788b27c8056619d17f9ce873</originalsourceid><addsrcrecordid>eNqFkc2LFDEQxYMo7jh686yNoCd7rKQ7XxdhaR1d3cWDLngLmXQyk6U7GZMexf_etDO4ehICVSS_vKrHQ-gxhhXGRLz60F2tAFMKNbA7aIFBipox-HoXLQAkrTFu-Bl6kPMNAG5bSu-jM8yBYKB8gT6-sZNNow968jFU0VVXF12e63m5jEaH3ofKxVR1c9vrKu_3q6r01doPerRhiodcrQ9h6x-ie04P2T461SW6Xr_90r2vLz-9u-jOL2vTynaqe84p7XtKuLQUmAG5YZJsiBHYWEYZBSOddpxyITaEGwGUMSx7zJ00VvBmiV4fdfeHzWh7U3ZIelD75Eedfqqovfr3Jfid2sbvCjMpmnKW6MVJIMVvB5snNfps7DDoYIsbxQQhlEryX5AAAdYALeDLI2hSzDlZ92cbDGqOSZWY1O-YVPmxRE_-dnALn3IpwPMToLPRg0s6GJ9vOdEwJuk899mR2_nt7odPVuk8qhszqrZVmKi2aWcXT4-Q01HpbSpC158J4AbKZgANaX4Bb1mttQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20206305</pqid></control><display><type>article</type><title>Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi</title><source>American Society for Microbiology</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Isham, N ; Ghannoum, M.A</creator><creatorcontrib>Isham, N ; Ghannoum, M.A</creatorcontrib><description>Candida and Aspergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for the organisms. The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined. The MICs of AMN for 25 strains each of non-Candida albicans Candida spp. (including Candida parapsilosis, Candida krusei, Candida guilliermondii, and Candida tropicalis), Aspergillus fumigatus, Scedosporium spp., Fusarium spp., and zygomycetes (including Absidia, Mucor, and Rhizopus spp.) were determined by using the Clinical and Laboratory Standards Institute M27-A2 and M38-A methodologies for yeasts and filamentous molds, respectively. The MIC ranges of AMN for all yeasts were similar (0.03 to 4.0 μg/ml), while the MIC ranges of AMN for filamentous fungi were species specific. AMN demonstrated potent antifungal activity against A. fumigatus, limited activity against Scedosporium spp., and no activity against zygomycetes or Fusarium spp. Our data showed that AMN demonstrated potent antifungal activities against all of the yeasts and Aspergillus isolates tested, suggesting that AMN could be an important addition to our arsenal of antifungals for the treatment of invasive fungal disease.</description><identifier>ISSN: 0095-1137</identifier><identifier>EISSN: 1098-660X</identifier><identifier>EISSN: 1098-5530</identifier><identifier>DOI: 10.1128/JCM.01550-06</identifier><identifier>PMID: 17021057</identifier><identifier>CODEN: JCMIDW</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Absidia ; Antifungal Agents - pharmacology ; Aspergillus - drug effects ; Aspergillus fumigatus ; Biological and medical sciences ; Candida - drug effects ; Candida guilliermondii ; Candida krusei ; Candida parapsilosis ; Candida tropicalis ; Fundamental and applied biological sciences. Psychology ; Fungi - drug effects ; Fusarium ; Fusarium - drug effects ; Humans ; Infectious diseases ; Lipopeptides ; Lipoproteins - pharmacology ; Medical sciences ; Microbial Sensitivity Tests ; Microbiology ; Miscellaneous ; Mucor ; Mycology ; Mycoses - microbiology ; Rhizopus ; Scedosporium ; Scedosporium - drug effects ; Zygomycetes</subject><ispartof>Journal of Clinical Microbiology, 2006-12, Vol.44 (12), p.4342-4344</ispartof><rights>2007 INIST-CNRS</rights><rights>Copyright © 2006, American Society for Microbiology 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-d7755dd5279e506c09b692b2c81ce65650c9faf75788b27c8056619d17f9ce873</citedby><cites>FETCH-LOGICAL-c494t-d7755dd5279e506c09b692b2c81ce65650c9faf75788b27c8056619d17f9ce873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698398/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698398/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,3189,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18366955$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17021057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Isham, N</creatorcontrib><creatorcontrib>Ghannoum, M.A</creatorcontrib><title>Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi</title><title>Journal of Clinical Microbiology</title><addtitle>J Clin Microbiol</addtitle><description>Candida and Aspergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for the organisms. The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined. The MICs of AMN for 25 strains each of non-Candida albicans Candida spp. (including Candida parapsilosis, Candida krusei, Candida guilliermondii, and Candida tropicalis), Aspergillus fumigatus, Scedosporium spp., Fusarium spp., and zygomycetes (including Absidia, Mucor, and Rhizopus spp.) were determined by using the Clinical and Laboratory Standards Institute M27-A2 and M38-A methodologies for yeasts and filamentous molds, respectively. The MIC ranges of AMN for all yeasts were similar (0.03 to 4.0 μg/ml), while the MIC ranges of AMN for filamentous fungi were species specific. AMN demonstrated potent antifungal activity against A. fumigatus, limited activity against Scedosporium spp., and no activity against zygomycetes or Fusarium spp. Our data showed that AMN demonstrated potent antifungal activities against all of the yeasts and Aspergillus isolates tested, suggesting that AMN could be an important addition to our arsenal of antifungals for the treatment of invasive fungal disease.</description><subject>Absidia</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus fumigatus</subject><subject>Biological and medical sciences</subject><subject>Candida - drug effects</subject><subject>Candida guilliermondii</subject><subject>Candida krusei</subject><subject>Candida parapsilosis</subject><subject>Candida tropicalis</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fungi - drug effects</subject><subject>Fusarium</subject><subject>Fusarium - drug effects</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Lipopeptides</subject><subject>Lipoproteins - pharmacology</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Mucor</subject><subject>Mycology</subject><subject>Mycoses - microbiology</subject><subject>Rhizopus</subject><subject>Scedosporium</subject><subject>Scedosporium - drug effects</subject><subject>Zygomycetes</subject><issn>0095-1137</issn><issn>1098-660X</issn><issn>1098-5530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2LFDEQxYMo7jh686yNoCd7rKQ7XxdhaR1d3cWDLngLmXQyk6U7GZMexf_etDO4ehICVSS_vKrHQ-gxhhXGRLz60F2tAFMKNbA7aIFBipox-HoXLQAkrTFu-Bl6kPMNAG5bSu-jM8yBYKB8gT6-sZNNow968jFU0VVXF12e63m5jEaH3ofKxVR1c9vrKu_3q6r01doPerRhiodcrQ9h6x-ie04P2T461SW6Xr_90r2vLz-9u-jOL2vTynaqe84p7XtKuLQUmAG5YZJsiBHYWEYZBSOddpxyITaEGwGUMSx7zJ00VvBmiV4fdfeHzWh7U3ZIelD75Eedfqqovfr3Jfid2sbvCjMpmnKW6MVJIMVvB5snNfps7DDoYIsbxQQhlEryX5AAAdYALeDLI2hSzDlZ92cbDGqOSZWY1O-YVPmxRE_-dnALn3IpwPMToLPRg0s6GJ9vOdEwJuk899mR2_nt7odPVuk8qhszqrZVmKi2aWcXT4-Q01HpbSpC158J4AbKZgANaX4Bb1mttQ</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Isham, N</creator><creator>Ghannoum, M.A</creator><general>American Society for Microbiology</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20061201</creationdate><title>Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi</title><author>Isham, N ; Ghannoum, M.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-d7755dd5279e506c09b692b2c81ce65650c9faf75788b27c8056619d17f9ce873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Absidia</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus fumigatus</topic><topic>Biological and medical sciences</topic><topic>Candida - drug effects</topic><topic>Candida guilliermondii</topic><topic>Candida krusei</topic><topic>Candida parapsilosis</topic><topic>Candida tropicalis</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fungi - drug effects</topic><topic>Fusarium</topic><topic>Fusarium - drug effects</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Lipopeptides</topic><topic>Lipoproteins - pharmacology</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Mucor</topic><topic>Mycology</topic><topic>Mycoses - microbiology</topic><topic>Rhizopus</topic><topic>Scedosporium</topic><topic>Scedosporium - drug effects</topic><topic>Zygomycetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Isham, N</creatorcontrib><creatorcontrib>Ghannoum, M.A</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Clinical Microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Isham, N</au><au>Ghannoum, M.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi</atitle><jtitle>Journal of Clinical Microbiology</jtitle><addtitle>J Clin Microbiol</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>44</volume><issue>12</issue><spage>4342</spage><epage>4344</epage><pages>4342-4344</pages><issn>0095-1137</issn><eissn>1098-660X</eissn><eissn>1098-5530</eissn><coden>JCMIDW</coden><abstract>Candida and Aspergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for the organisms. The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined. The MICs of AMN for 25 strains each of non-Candida albicans Candida spp. (including Candida parapsilosis, Candida krusei, Candida guilliermondii, and Candida tropicalis), Aspergillus fumigatus, Scedosporium spp., Fusarium spp., and zygomycetes (including Absidia, Mucor, and Rhizopus spp.) were determined by using the Clinical and Laboratory Standards Institute M27-A2 and M38-A methodologies for yeasts and filamentous molds, respectively. The MIC ranges of AMN for all yeasts were similar (0.03 to 4.0 μg/ml), while the MIC ranges of AMN for filamentous fungi were species specific. AMN demonstrated potent antifungal activity against A. fumigatus, limited activity against Scedosporium spp., and no activity against zygomycetes or Fusarium spp. Our data showed that AMN demonstrated potent antifungal activities against all of the yeasts and Aspergillus isolates tested, suggesting that AMN could be an important addition to our arsenal of antifungals for the treatment of invasive fungal disease.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>17021057</pmid><doi>10.1128/JCM.01550-06</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0095-1137 |
| ispartof | Journal of Clinical Microbiology, 2006-12, Vol.44 (12), p.4342-4344 |
| issn | 0095-1137 1098-660X 1098-5530 |
| language | eng |
| recordid | cdi_highwire_asm_jcm_44_12_4342 |
| source | American Society for Microbiology; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Absidia Antifungal Agents - pharmacology Aspergillus - drug effects Aspergillus fumigatus Biological and medical sciences Candida - drug effects Candida guilliermondii Candida krusei Candida parapsilosis Candida tropicalis Fundamental and applied biological sciences. Psychology Fungi - drug effects Fusarium Fusarium - drug effects Humans Infectious diseases Lipopeptides Lipoproteins - pharmacology Medical sciences Microbial Sensitivity Tests Microbiology Miscellaneous Mucor Mycology Mycoses - microbiology Rhizopus Scedosporium Scedosporium - drug effects Zygomycetes |
| title | Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A03%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20MICs%20of%20Aminocandin%20for%20Candida%20spp.%20and%20Filamentous%20Fungi&rft.jtitle=Journal%20of%20Clinical%20Microbiology&rft.au=Isham,%20N&rft.date=2006-12-01&rft.volume=44&rft.issue=12&rft.spage=4342&rft.epage=4344&rft.pages=4342-4344&rft.issn=0095-1137&rft.eissn=1098-660X&rft.coden=JCMIDW&rft_id=info:doi/10.1128/JCM.01550-06&rft_dat=%3Cproquest_highw%3E20206305%3C/proquest_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20206305&rft_id=info:pmid/17021057&rfr_iscdi=true |